URGENT: This Altcoin Opportunity Won’t Wait – Act Now

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

Emily Luisa Hill net worth and biography

Emily Hill Biography and Net Worth

CFO of PTC Therapeutics

Emily Hill joined PTC Therapeutics in November 2013 and was most recently Senior Vice President and Head of Investor Relations. In her new role, Ms. Hill will continue to work with the Executive Committee to execute the Company’s long-term strategy. Prior to joining PTC Therapeutics, Emily was Director of Investor Relations of Warner Chilcott where she was responsible for leading the function. Additionally, Ms. Hill was Senior Manager of Investor Relations at Genzyme Corporation. Prior to Genzyme, Emily was a Biotech Equity Research Associate at Summer Street Partners. Ms. Hill has an MBA, with a concentration in Finance from Fordham University, and a degree in Pharmacology from Tufts University School of Biomedical Research and a BA from Hamilton College.

What is Emily Luisa Hill's net worth?: The estimated net worth of Emily Luisa Hill is at least $4.67 million as of August 16th, 2024. Ms. Hill owns 101,057 shares of PTC Therapeutics stock worth more than $4,672,876 as of December 21st. This net worth evaluation does not reflect any other investments that Ms. Hill may own. Learn More about Emily Luisa Hill's net worth.
How do I contact Emily Luisa Hill?: The corporate mailing address for Ms. Hill and other PTC Therapeutics executives is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. PTC Therapeutics can also be reached via phone at (908) 222-7000 and via email at [email protected]. Learn More on Emily Luisa Hill's contact information.
Has Emily Luisa Hill been buying or selling shares of PTC Therapeutics?: Emily Luisa Hill has not been actively trading shares of PTC Therapeutics in the last ninety days. Most recently, Emily Luisa Hill sold 7,363 shares of the business's stock in a transaction on Monday, March 27th. The shares were sold at an average price of $45.00, for a transaction totalling $331,335.00. Following the completion of the sale, the chief financial officer now directly owns 38,925 shares of the company's stock, valued at $1,751,625. Learn More on Emily Luisa Hill's trading history.
Who are PTC Therapeutics' active insiders?: PTC Therapeutics' insider roster includes Neil Almstead (Insider), Mark Boulding (VP), Pierre Gravier (CFO), Emily Hill (CFO), Allan Jacobson (Director), Matthew Klein (COO), Stephanie Okey (Director), Eric Pauwels (Insider), Stuart Peltz (CEO), Emma Reeve (Director), Michael Schmertzler (Director), David Southwell (Director), Dawn Svoronos (Director), Christine Utter (CAO), Alethia Young (Chief Financial Officer, Bicycle Therapeutics), and Jerome Zeldis (Director). Learn More on PTC Therapeutics' active insiders.
Are insiders buying or selling shares of PTC Therapeutics?: During the last twelve months, insiders at the biopharmaceutical company sold shares 20 times. They sold a total of 253,856 shares worth more than $12,039,652.16. The most recent insider tranaction occured on December, 2nd when insider Neil Gregory Almstead sold 69,550 shares worth more than $3,620,773.00. Insiders at PTC Therapeutics own 5.5% of the company. Learn More about insider trades at PTC Therapeutics.
Information on this page was last updated on 12/2/2024.

Emily Luisa Hill Insider Trading History at PTC Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/27/2023	Sell	7,363	$45.00	$331,335.00	38,925
1/31/2023	Sell	575	$45.63	$26,237.25	46,288
1/24/2023	Sell	223	$47.45	$10,581.35	46,863
1/11/2023	Sell	418	$44.36	$18,542.48	47,086
1/9/2023	Sell	758	$41.66	$31,578.28	48,001
3/31/2022	Sell	7,910	$37.78	$298,839.80
2/1/2022	Sell	553	$40.00	$22,120.00
1/25/2022	Sell	211	$39.31	$8,294.41
1/7/2022	Sell	800	$38.52	$30,816.00
1/4/2022	Sell	173	$41.16	$7,120.68
2/1/2021	Sell	541	$56.96	$30,815.36	23,306
1/25/2021	Sell	275	$62.05	$17,063.75	23,847
1/8/2021	Sell	26,033	$69.75	$1,815,801.75	26,552
1/5/2021	Sell	288	$62.37	$17,962.56	13,498
6/29/2020	Sell	2,581	$52.50	$135,502.50	13,610
1/23/2020	Sell	330	$53.25	$17,572.50	6,891
1/6/2020	Sell	321	$48.17	$15,462.57	7,484

Emily Luisa Hill Buying and Selling Activity at PTC Therapeutics

PTC Therapeutics Company Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Today's Range

Now: $46.24

$44.74

$47.42

50 Day Range

MA: $43.50

$36.70

$52.07

2 Week Range

Now: $46.24

$23.58

$54.16

Volume

1,431,601 shs

Average Volume

849,432 shs

Market Capitalization

$3.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.